Receptor for Advanced Glycation End Products: Dementia and Cognitive Impairment.
Level 5 - mechanism / opinion, no new human data
Narrative review describing biological mechanisms without systematic review methodology or primary human data.
PubMed 36889338 · doi:10.1055/a-2015-8041
What was done
The authors conducted a narrative review examining the role of the receptor for advanced glycation end products (RAGE) and advanced glycation end products (AGEs) in the pathophysiology, early diagnosis, and potential targeted management of dementia, Alzheimer's disease, and cognitive impairment.
What was found
The abstract reports no numerical data or empirical findings. It describes the mechanistic cascade in which vascular dysfunction-derived AGEs and amyloid-beta bind to RAGE, triggering reactive oxygen species generation, accelerating amyloid-beta accumulation, driving senile plaque and neurofibrillary tangle development, and involving microglial activation. The authors suggest RAGE may serve as an earlier biomarker than amyloid-beta.
Why it matters
It highlights RAGE as a mechanistic bridge between vascular/metabolic dysfunction and Alzheimer's pathology, supporting the conceptual development of RAGE-targeted diagnostic probes and therapeutics.
Limits
As a narrative review, it lacks a systematic literature search, quality appraisal, or primary experimental data. The abstract provides no quantitative metrics regarding diagnostic accuracy, effect sizes, or clinical outcomes in human populations.
Cited by
- supports Beta-amyloid and phosphorylated tau bind to RAGE (receptor for advanced glycation end products) on microglial cell surfaces.